Cannabidiol

International Superstar and Business Mogul Flo Rida's JettSet1 Enterprises and Biom Therapeutics Partner To Bring the First and Only Cannabinoid-Derived, FDA Approved Orphan Status Therapeutic Agent To Treat 'Angelman Syndrome'

Retrieved on: 
Monday, June 19, 2023

).Biom Therapeutics is a preclinical-stage company which has an initial focus on rare childhood diseases.

Key Points: 
  • ).Biom Therapeutics is a preclinical-stage company which has an initial focus on rare childhood diseases.
  • Biom Therapeutics has extensively researched Cannabidiol (CBD)-based drugs and their efficacy in specifically treating neurodevelopmental conditions.
  • Biom Therapeutics' patent-pending water-soluble CBD, nano-dispersion, sugar-free, child-friendly formulations improve effectiveness and treatment compliance.
  • The FDA designated the lead drug candidate, BIO017, the first and only therapeutic agent with orphan drug approval status in March 2021 for the treatment of Angelman Syndrome.

IGC Pharma Receives Notice of Allowance for Patent on Seizures

Retrieved on: 
Tuesday, June 6, 2023

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that it has received a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (IGC-501).

Key Points: 
  • IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that it has received a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (IGC-501).
  • The formulation also received an intent to grant from the European Patent Office.
  • With these awards, and a previous one, the formulation for treating seizures is protected in the U.S., Canada, and certain European countries.
  • IGC provided animal data, with dogs, on the reduction in the number of seizures by using a combination of cannabidiol (CBD) and phenobarbital versus either alone.

Global Functional Beverages Market Report 2023: Sector is Expected to Reach $205.1 Billion by 2028 at a CAGR of 8.55% - ResearchAndMarkets.com

Retrieved on: 
Friday, June 2, 2023

Sports drinks, energy drinks, herbal tea, vitamin water, and fruit drinks with additives are some commonly available functional beverages.

Key Points: 
  • Sports drinks, energy drinks, herbal tea, vitamin water, and fruit drinks with additives are some commonly available functional beverages.
  • Functional beverages assist in delivering nutrients and bioactive compounds to the body, including antioxidants, fatty acids, fibers, plant extracts, and micronutrients.
  • Furthermore, recent innovations in packaging, such as single-serve and ready-to-drink (RTD) packaging, to address the rising demand for convenient functional beverages are supporting the market growth.
  • The publisher provides an analysis of the key trends in each sub-segment of the global functional beverages market report, along with forecasts at the global, regional and country level from 2023-2028.

U.S. product recalls hit four-year high in first quarter of 2023

Retrieved on: 
Thursday, May 25, 2023

MEMPHIS, Tenn., May 25, 2023 /PRNewswire/ -- Data from the first quarter of 2023 shows that the number of product recalls in the U.S. increased 14.2% from the previous quarter. According to Sedgwick brand protection's latest U.S. product recall index report — which analyzes recall data from five key industries — this marks the highest single-quarter total in four years.

Key Points: 
  • Sedgwick brand protection releases Q1 U.S. product recall index report
    MEMPHIS, Tenn., May 25, 2023 /PRNewswire/ -- Data from the first quarter of 2023 shows that the number of product recalls in the U.S. increased 14.2% from the previous quarter.
  • The consumer product industry recorded the most recalls in a single quarter since Q3 2015, with 94 events.
  • The number of units recalled also increased significantly from the previous quarter, up 442.1% to 23.1 million units.
  • Q1 2023 marked the most pharmaceutical recalls in a single quarter in the past 18 years, with 144 events.

WEED Australia Ltd is Proud to Announce the Appointment of Ms. Amanda Brunskill-Scott and Mrs. Nicole Breen as Members of our Board of Directors

Retrieved on: 
Wednesday, May 17, 2023

In addition, Ms. Brunskill-Scott has been appointed as our in-house counsel for both WEED Australia Limited and the Cannabis Institute of Australia.

Key Points: 
  • In addition, Ms. Brunskill-Scott has been appointed as our in-house counsel for both WEED Australia Limited and the Cannabis Institute of Australia.
  • I am excited to work with Amanda and bring WEED Australia to its full potential in the cannabis and hemp space.
  • WEED Australia Ltd. formed in March 2017 was the first cannabis pubco, ASIC regulated, in Australia with an American parent.
  • WEED Hong Kong Ltd. Director Nicole Breen agrees, "The pandemic has affected all of us on a worldwide basis.

Pet CBD Club Announces New Line of CBD Products for Cats and Dogs, Designed to Promote Pet Well-Being

Retrieved on: 
Friday, May 12, 2023

Mayville, North Dakota--(Newsfile Corp. - May 12, 2023) - Pet CBD Club , a leading provider of CBD products for pets, is excited to announce the launch of their new line of CBD products specifically formulated for cats and dogs.

Key Points: 
  • Mayville, North Dakota--(Newsfile Corp. - May 12, 2023) - Pet CBD Club , a leading provider of CBD products for pets, is excited to announce the launch of their new line of CBD products specifically formulated for cats and dogs.
  • The new products, CBD For Cats and CBD For Dogs, are designed to promote overall pet health and well-being.
  • By offering high-quality CBD products, Pet CBD Club aims to help pets live their best lives, free from anxiety, pain, and other common issues that can affect their overall health and happiness.
  • The CBD For Cats and CBD For Dogs products offered by Pet CBD Club are formulated with the highest quality, organically grown hemp-derived CBD.

Global Cannabis Testing Market Report 2023: Rising Number of Advanced Laboratories Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 11, 2023

Cannabis, also known as marijuana, is obtained from the dried flowers, leaves, stems, and seeds of the Cannabis sativa or Cannabis indica plant.

Key Points: 
  • Cannabis, also known as marijuana, is obtained from the dried flowers, leaves, stems, and seeds of the Cannabis sativa or Cannabis indica plant.
  • In line with this, the growing number of advanced laboratories to conduct cannabis testing is presently offering a favorable market outlook.
  • Besides this, the rising legalization of medical cannabis to treat various diseases is offering lucrative growth opportunities to industry investors.
  • Moreover, the increasing awareness among the masses about the benefits of cannabis testing through conferences, symposia, and workshops is propelling the growth of the market.

22nd Century Group (Nasdaq: XXII) Reports First Quarter 2023 Financial Results, Introduces 2023 Full Year Revenue Outlook

Retrieved on: 
Tuesday, May 9, 2023

We again reported record cannabinoid ingredient volumes delivered in the first quarter, a trend we expect to further increase throughout 2023.

Key Points: 
  • We again reported record cannabinoid ingredient volumes delivered in the first quarter, a trend we expect to further increase throughout 2023.
  • “We believe 22nd Century is poised for phenomenal growth this year in both our tobacco and hemp/cannabis businesses.
  • Operating loss for the first quarter of 2023 was $17.8 million, compared to $8.1 million in the prior year period.
  • During the webcast, James A. Mish, chief executive officer of 22nd Century Group, John Miller, president of 22nd Century’s tobacco business, and Hugh Kinsman, chief financial officer, will provide an update on the Company.

Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A

Retrieved on: 
Tuesday, May 2, 2023

The Phase 1 trial measured the safety, tolerability, and pharmacokinetic profiles of IHL-675A compared to the reference listed drugs, Epidiolex (CBD) and Plaquenil (HCQ).

Key Points: 
  • The Phase 1 trial measured the safety, tolerability, and pharmacokinetic profiles of IHL-675A compared to the reference listed drugs, Epidiolex (CBD) and Plaquenil (HCQ).
  • Three cohorts of 12 participants (n = 36) received either IHL-675A, CBD or HCQ and the clinical assessments were identical across the three arms of the trial.
  • The trial was conducted by CMAX Clinical Research in Adelaide, South Australia and managed by Avance Clinical.
  • Incannex Chief Scientific Officer Dr Mark Bleackley said: “The results from the Phase 1 trial are a critical milestone in the development of IHL-675A.

Charlotte's Web Expands Distribution with America's Largest National Distributor in Pet Specialty, Phillips Pet Food & Supplies

Retrieved on: 
Monday, May 1, 2023

LOUISVILLE, Colo., May 1, 2023 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in cannabidiol ("CBD") hemp extract wellness products is pleased to add Phillips Pet Food & Supplies ("Phillips"), America's largest distributor in the pet specialty retail channel, covering more than 6,000 retailers representing more than 14,000 retail locations.

Key Points: 
  • LOUISVILLE, Colo., May 1, 2023 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in cannabidiol ("CBD") hemp extract wellness products is pleased to add Phillips Pet Food & Supplies ("Phillips"), America's largest distributor in the pet specialty retail channel, covering more than 6,000 retailers representing more than 14,000 retail locations.
  • Phillips boasts a broad assortment of pet specialty retail, paired with comprehensive customer touchpoints to drive engagement across its national footprint from independent boutique pet stores to regional chains and national chains and mass retailers.
  • Initial orders have been shipped and Phillips will distribute the full line of Charlotte's Web pet products, including topical pet products, and functionally focused CBD dog chews with synergistic ingredients to support specific health functions; Calming, Hips & Joints, and Cognition.
  • "We are thrilled to have Phillips as our national distribution partner for pet products.